Gryphon Financial Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.8M | Buy |
91,042
+2,062
| +2% | +$457K | 2.03% | 8 |
|
|
2025
Q4 | $20.3M | Buy |
88,980
+1,045
| +1% | +$238K | 2.18% | 9 |
|
|
2025
Q3 | $20.4M | Sell |
87,935
-3,433
| -4% | -$699K | 2.32% | 10 |
|
|
2025
Q2 | $17M | Buy |
91,368
+4,898
| +6% | +$910K | 2.21% | 7 |
|
|
2025
Q1 | $18.1M | Buy |
86,470
+391
| +0.5% | +$76K | 2.61% | 4 |
|
|
2024
Q4 | $15.3M | Buy |
86,079
+903
| +1% | +$166K | 2.19% | 9 |
|
|
2024
Q3 | $16.8M | Sell |
85,176
-776
| -0.9% | -$145K | 2.27% | 7 |
|
|
2024
Q2 | $14.7M | Buy |
85,952
+1,490
| +2% | +$247K | 2.21% | 7 |
|
|
2024
Q1 | $15.4M | Buy |
84,462
+213
| +0.3% | +$36.7K | 2.56% | 6 |
|
|
2023
Q4 | $13M | Buy |
84,249
+1,531
| +2% | +$223K | 2.29% | 7 |
|
|
2023
Q3 | $12.3M | Sell |
82,718
-354
| -0.4% | -$52K | 2.86% | 5 |
|
|
2023
Q2 | $11.2M | Sell |
83,072
-46
| -0.1% | -$6.75K | 2.42% | 11 |
|
|
2023
Q1 | $13.2M | Sell |
83,118
-24
| -0% | -$3.67K | 3.01% | 6 |
|
|
2022
Q4 | $13.4M | Buy |
83,142
+91
| +0.1% | +$14K | 3.2% | 5 |
|
|
2022
Q3 | $11.1M | Buy |
83,051
+1,079
| +1% | +$155K | 2.81% | 6 |
|
|
2022
Q2 | $12.6M | Sell |
81,972
-847
| -1% | -$129K | 3.05% | 6 |
|
|
2022
Q1 | $13.4M | Sell |
82,819
-1,095
| -1% | -$159K | 2.73% | 7 |
|
|
2021
Q4 | $11.4M | Sell |
83,914
-261
| -0.3% | -$30.8K | 2.15% | 11 |
|
|
2021
Q3 | $9.08M | Buy |
84,175
+1,526
| +2% | +$174K | 2.02% | 11 |
|
|
2021
Q2 | $9.28M | Sell |
82,649
-1,891
| -2% | -$213K | 2.09% | 10 |
|
|
2021
Q1 | $9.15M | Buy |
84,540
+2,783
| +3% | +$298K | 2.08% | 11 |
|
|
2020
Q4 | $8.76M | Buy |
81,757
+1,456
| +2% | +$140K | 2.26% | 9 |
|
|
2020
Q3 | $7.03M | Buy |
80,301
+548
| +0.7% | +$51.6K | 2.08% | 11 |
|
|
2020
Q2 | $7.83M | Sell |
79,753
-92
| -0.1% | -$8.1K | 2.43% | 9 |
|
|
2020
Q1 | $6.08M | Sell |
79,845
-2,122
| -3% | -$181K | 2.24% | 10 |
|
|
2019
Q4 | $7.26M | Buy |
81,967
+1,909
| +2% | +$158K | 1.88% | 13 |
|
|
2019
Q3 | $6.06M | Sell |
80,058
-1,530
| -2% | -$105K | 1.75% | 13 |
|
|
2019
Q2 | $5.93M | Buy |
81,588
+1,186
| +1% | +$93.2K | 1.71% | 14 |
|
|
2019
Q1 | $6.48M | Sell |
80,402
-572
| -0.7% | -$46.8K | 1.91% | 14 |
|
|
2018
Q4 | $7.46M | Sell |
80,974
-340
| -0.4% | -$29.9K | 1.9% | 11 |
|
|
2018
Q3 | $7.69M | Sell |
81,314
-1,381
| -2% | -$131K | 2.3% | 10 |
|
|
2018
Q2 | $7.66M | Sell |
82,695
-77
| -0.1% | -$7.52K | 3.46% | 7 |
|
|
2018
Q1 | $7.83M | Sell |
82,772
-1,216
| -1% | -$134K | 4.01% | 6 |
|
|
2017
Q4 | $8.12M | Buy |
+83,988
| New | +$7.92M | 4.62% | 5 |
|
Other funds holding ABBV
VCM
VPM
Gryphon Financial Partners's ABBV Position: Q1 2026 in Review
Gryphon Financial Partners increased its AbbVie (ABBV) stake by 2.3% in Q1 2026, buying an estimated $457K and bringing the position to 91,042 shares worth $19.8M. The position accounts for 2.03% of the portfolio, ranked #8.
Gryphon Financial Partners first reported a position in ABBV in Q4 2017 and has held it in 34 quarters since. The position peaked at $20.4M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Gryphon Financial Partners held 91,042 shares of AbbVie worth $19.8M as of Q1 2026.
- Gryphon Financial Partners bought 2,062 AbbVie shares in Q1 2026, an estimated $457K.
- AbbVie made up 2.03% of Gryphon Financial Partners's portfolio in Q1 2026, its #8 holding.
- Gryphon Financial Partners first reported a position in AbbVie in Q4 2017 and has held it in 34 quarters since.
- Gryphon Financial Partners's AbbVie position peaked at $20.4M in Q3 2025.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Gryphon Financial Partners's 13F filing for Q1 2026, filed 6 May 2026.